We then investigated the role of ACSL4 and ACOT2 in the production of lipooxygenase metabolites by disrupting the expression of endogenous ACSL4 and ACOT2 in MDA-MB-231 breast cancer cells. This evidence concerns the gene ACSL4 and breast carcinoma.